Avantium and Origin Partner on PEF

Avantium is partnering with Origin Materials to accelerate the mass production of furandicarboxylic acid (FDCA) and plant-based, fully recyclable plastic, polyethylene furanoate (PEF).

The partnership will combine Avantium’s proprietary YXY process with Origin’s patented technology platform that turns carbon found in sustainable wood residues into building-block chemicals such as chloromethylfurfural (CMF), which can be used to make FDCA.

The company has already started to build a commercial-scale FDCA plant in Delfzijl, the Netherlands, while Origin reached mechanical completion this month on its first commercial manufacturing plant for CMF and derivatives in Sarnia, Canada, with start-up expected in the second quarter of 2023.   

Under their collaboration, Avantium has granted Origin a non-exclusive license to use certain parts of its YXY process – including certain patent rights – for enabling the conversion of CMF derivatives into FDCA at a 100,000 t/y plant. Avantium added that it will also develop a “bridge” between the companies’ respective technologies.

© Shutterstock/Africa Studio
© Shutterstock/Africa Studio

Origin paid Avantium €5 million upfront last year and will also pay a milestone fee of €7.5 million, as well as subsequent license fees upon achieving certain development milestones.

"The technologies of both companies are highly complementary and will also enable the use of non-edible, renewable feedstocks for the production of FDCA and PEF, meeting the expectations of brand owners and consumers worldwide,” said Avantium CEO Tom van Aken.

The partners have also entered into a conditional offtake agreement whereby Avantium will sell FDCA and PEF to Origin Materials from its FDCA pilot plant in Geleen, the Netherlands, in 2023 and from the Delfzjil plant once it goes into commercial operation in 2024.

Author: Elaine Burridge, Freelance Journalist

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.